In Europe, whooping cough (Pertussis) is in the increase, with more than 20.000 cases reported annually. Often infants fall victim to the disease, where it can be life-threatening. Possible complications include pneumonia, brain damage and collapsed lungs, leading to death in one in 200.
There is a vaccine on the market, but a newborn’s immune system is too immature to respond to it. Therefore scientists at the Institute Pasteur in Lille, France have developed a new vaccine that the babies’ immune system can deal with: it is administered intranasally to reproduce the natural conditions of infection as closely as possible.
The new substance is currently undergoing clinical trials and has passed the first phase of testing on human adults successfully.
The results were published on the last issue of the peer-reviewed journal “Plos One”.
About the author: Eurasia Review
Eurasia Review is an independent Journal and Think Tank that provides a venue for analysts and experts to disseminate content on a wide-range of subjects that are often overlooked or under-represented by Western dominated media.
Despite the combined Eurasia and Afro-Asia areas containing over 70% of the world’s population, analysis and news continues to be dominated by a U.S. slant, and that is where Eurasia Review enters the picture by providing alternative, in-depth perspectives on current events.